Trexquant Investment LP lifted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 14.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 635,847 shares of the company's stock after acquiring an additional 80,345 shares during the period. Trexquant Investment LP owned approximately 0.75% of Verve Therapeutics worth $3,586,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. State Street Corp boosted its position in Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company's stock worth $20,586,000 after purchasing an additional 903,809 shares during the period. Geode Capital Management LLC boosted its position in shares of Verve Therapeutics by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company's stock worth $9,172,000 after buying an additional 25,093 shares during the period. FMR LLC boosted its position in shares of Verve Therapeutics by 0.3% in the third quarter. FMR LLC now owns 1,418,993 shares of the company's stock worth $6,868,000 after buying an additional 3,873 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Verve Therapeutics by 28.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company's stock valued at $2,769,000 after buying an additional 126,110 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Verve Therapeutics by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 361,498 shares of the company's stock valued at $2,039,000 after buying an additional 14,469 shares during the period. Hedge funds and other institutional investors own 97.11% of the company's stock.
Verve Therapeutics Price Performance
Shares of NASDAQ:VERV traded up $0.21 during midday trading on Friday, reaching $3.26. The company had a trading volume of 2,382,497 shares, compared to its average volume of 1,460,202. The stock has a market capitalization of $289.47 million, a P/E ratio of -1.33 and a beta of 1.86. The stock's fifty day moving average price is $5.99 and its 200-day moving average price is $5.93. Verve Therapeutics, Inc. has a one year low of $2.86 and a one year high of $9.31.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. As a group, sell-side analysts forecast that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have issued reports on VERV shares. Royal Bank of Canada lowered their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Finally, Guggenheim reissued a "buy" rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $20.67.
Read Our Latest Research Report on VERV
About Verve Therapeutics
(
Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Read More
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
